<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>From 1973 through 1987 25 patients underwent mitral valve replacement in the first year of life for <z:hpo ids='HP_0001718'>mitral stenosis</z:hpo> and <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The patients with <z:hpo ids='HP_0001718'>mitral stenosis</z:hpo> included two with mitral arcade, two with supravalvular <z:hpo ids='HP_0001718'>mitral stenosis</z:hpo> with hypoplastic mitral valve, and one with <z:hpo ids='HP_0011571'>parachute mitral valve</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Included in the group of patients with <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> were 12 with <z:hpo ids='HP_0006695'>atrioventricular canal defect</z:hpo>, six with chordal and leaflet defects, one with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e>, and one with <z:hpo ids='HP_0006689'>bacterial endocarditis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Prostheses included 12 Bj√∂rk-Shiley (17 mm), seven St </plain></SENT>
<SENT sid="4" pm="."><plain>Jude Medical (19 mm in four, 21 mm in three), five stent-mounted dura mater valves (12 mm to 16 mm), and one porcine xenograft (19 mm) </plain></SENT>
<SENT sid="5" pm="."><plain>In four patients the valves were placed in the left atrium in a supraannular location </plain></SENT>
<SENT sid="6" pm="."><plain>There were nine operative (<z:hpo ids='HP_0006695'>atrioventricular canal defect</z:hpo> seven, <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo> two) and five late (<z:hpo ids='HP_0006695'>atrioventricular canal defect</z:hpo> four, <z:hpo ids='HP_0001718'>mitral stenosis</z:hpo> one) <z:hpo ids='HP_0011420'>deaths</z:hpo>, giving actuarial 1- and 5-year survival rates of 52% and 43%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 6 patients with tissue valves died; the four with supraannular mitral valve replacement survived </plain></SENT>
<SENT sid="8" pm="."><plain>Since 1983 operative mortality has been reduced to 0% (70% confidence limits 0% to 24%) </plain></SENT>
<SENT sid="9" pm="."><plain>Nine patients required a second mitral valve replacement for prosthetic stenosis 5 to 69 (mean 30) months after the original mitral valve replacement (one operative <z:hpo ids='HP_0011420'>death</z:hpo>) </plain></SENT>
<SENT sid="10" pm="."><plain>Because of improvements in repair of <z:hpo ids='HP_0006695'>atrioventricular canal defect</z:hpo> in infancy, the need for mitral valve replacement at <z:hpo ids='HP_0006695'>atrioventricular canal defect</z:hpo> repair has decreased </plain></SENT>
<SENT sid="11" pm="."><plain>Although valvuloplasty has been advocated for repair of congenital <z:e sem="disease" ids="C0264765,C0026265" disease_type="Disease or Syndrome" abbrv="">mitral valve disease</z:e> and is applicable in some infants with <z:hpo ids='HP_0001653'>mitral regurgitation</z:hpo>, mitral valve replacement is frequently unavoidable for congenital <z:e sem="disease" ids="C0865573" disease_type="Disease or Syndrome" abbrv="">mitral disease</z:e> and can now be accomplished at a low operative risk, even when the prosthesis has to be positioned supraannularly </plain></SENT>
</text></document>